Westlake Chemical Partners LP Announces Second Quarter 2026 Results

Westlake Chemical Partners LP (NYSE: WLKP) reported Q2 2026 net income attributable to the partnership of $14.2 million, or $0.40 per limited partner unit, versus $14.6 million in Q2 2025. Operating cash flow was $129.8 million. It declared a $0.4714 per unit distribution, 48th consecutive quarter, with trailing twelve-month coverage of 1.04x. Credit facilities were amended to extend maturities to July 2031.

Original reporting
Published Aug 4, 2026, 11:00 AM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Aug 4, 2026, 11:12 AM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
alphai market briefEarnings
Primary signal
$WLKP
Bullish
medium confidence
Mentioned
$WLKP
Relevance
8/10
alphai data visualization · based on finanznachrichten.de
Decision brief

The 30-second read

$WLKPBullishMed
01

Why it matters

Traders can update income expectations using the declared distribution, trailing coverage ratio, and the credit facility maturity extension, while monitoring ethylene margin and turnaround-related capex normalization.

02

Market read

A same-day earnings and distribution update with coverage above 1.0x and improved financing runway can move MLP income positioning.

03

What to watch

Distributable cash flow changes are partly driven by working capital and prior-year turnaround effects, which may not repeat in subsequent quarters.

Relevance 8/10Novelty 7/10Timing: distribution payable Aug. 28, 2026, record Aug. 13, 2026

Background

Westlake Chemical Partners LP is an MLP with cash flows tied to ethylene production and a sales agreement with Westlake, plus periodic turnaround-driven capex swings.

Company-level read

Ticker impact

$WLKPBullishMedium confidence
Context

Westlake Chemical Partners LP reported Q2 2026 net income of $14.2M, declared a $0.4714/unit distribution, and extended credit maturities to 2031.

Expected impact

Moderately positive bias for WLKP as coverage remains above 1.0x and the credit facility maturity extension reduces refinancing risk.

Evidence & confidence

Q2 distributable cash flow rose year over year, trailing twelve-month coverage is 1.04x versus 1.00x at end of Q1, and the distribution is the 48th consecutive payment. The credit agreement amendment to July 2031 is a tangible balance-sheet risk reducer, though no explicit forward guidance numbers are provided.

Market effects

Reinforces the MLP/ethylene-linked cash-flow model where third-party ethylene margins and turnaround capex timing drive distributable cash flow.

Limited direct regional read-through; primarily impacts US-listed MLP income sentiment.

Ethylene margin sensitivity ties results to global commodity conditions, but the article provides no new global demand datapoint.

Counterpoint

Coverage is only 1.04x, so the distribution may still be vulnerable if ethylene margins or maintenance capex assumptions deteriorate.

Key entities

  • Westlake Chemical Partners LP

    Reports Q2 2026 results, declares $0.4714/unit distribution, and discloses trailing twelve-month coverage of 1.04x.

  • Westlake Chemical OpCo LP

    Ethylene sales agreement sells 95% of ethylene production to Westlake for a $0.10/lb cash margin.

  • Westlake Corporation

    Amendments to revolving credit agreements and the ethylene sales agreement underpin OpCo cash-flow stability.

Related articles

$WLKPMed

Westlake Chemical Partners LP (WLKP): Results of Operations and Financial Condition

Westlake Chemical Partners LP (WLKP) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 ex991_20260630earningsrele.htm EX-99.1 Document EXHIBIT 99.1 WESTLAKE CHEMICAL PARTNERS LP Contact—(713) 585-2900 Investors—Jonathan Baksht Media—L. Benjamin Ederington Westlake Chemical Partners LP Announces Second Quarter 2026 Results • Declared quarterly distribution

$KDMed

Kyndryl Q1 Earnings Call Highlights

Kyndryl (NYSE:KD) Q1 call said demand is rising for AI deployment, hybrid modernization, cybersecurity and data-residency. It reported 40 deals worth over $50M in 12 months, with 10 in Q1, and Kyndryl Consult signings up 50%. IBM relationship changes are expected to weigh on constant-currency revenue through FY2027. FCF was -$401M; cash $2.1B. Outlook FY2027 reaffirmed.

$KAIMedAI 8/10

Kadant Q2 Earnings Call Highlights

Kadant (NYSE:KAI) reported Q2 equipment backlog of $182 million and said aftermarket demand stayed at record or near-record levels. Flow Control revenue rose 5% to $100 million; Industrial Processing revenue rose to a record $144 million; Material Handling bookings were $73 million. Q2 gross margin fell to 43.8%. Kadant raised FY revenue guidance to $1.19-$1.21B and adjusted EPS to $12.43-$12.68.

$KRPMed

Kimbell Royalty Q2 Earnings Call Highlights

Kimbell Royalty (NYSE:KRP) reported record Q2 adjusted EBITDA of $84.9 million, with cash G&A of $5.9 million ($2.50 per BOE). It declared a $0.47 per common unit cash distribution, up 15% QoQ, and said 47% may be return of capital. The borrowing base rose to $660 million; debt was $478.7 million. Rig activity and production varied by basin.

$KMPRMed

Kemper Q2 Earnings Call Highlights

Kemper (NYSE:KMPR) reported Q2 results and discussed credit-loss allowances tied to surplus notes in its reciprocal exchange, including a $21 million pre-tax charge on $36 million of notes. Holding-company liquidity was $766 million and debt-to-capital rose to 28.3%. Personal auto normalized combined ratio was 102% and commercial 93.7%, with California rate actions and restructuring savings over $80 million run-rate.

$KOPMed

Koppers Q2 Earnings Call Highlights

Koppers (NYSE:KOP) reported Q2 updates on capital spending of about $24M, shareholder returns of $47M, and debt reduction of $22M in the first half. Liquidity was $390M with net debt of $857M and net leverage at 3.5x. The board raised its dividend to $0.09/share. KOP kept 2026 sales guidance at $1.9B-$2.0B but cut adjusted EBITDA to $240M-$250M and EPS to $3.80-$4.20.